| Year |
Citation |
Score |
| 2019 |
Marcar L, Bardhan K, Gheorghiu L, Dinkelborg P, Pfäffle H, Liu Q, Wang M, Piotrowska Z, Sequist LV, Borgmann K, Settleman JE, Engelman JA, Hata AN, Willers H. Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity. Cell Reports. 27: 3422-3432.e4. PMID 31216465 DOI: 10.1016/j.celrep.2019.05.058 |
0.367 |
|
| 2017 |
Wang VE, Doench J, Root D, Bernards R, Settleman J, McCormick F. Abstract 3182: Cytoskeletal modulation results in increased tumor survival and drug resistance through attenuation of p53 dependent apoptosis Cancer Research. 77: 3182-3182. DOI: 10.1158/1538-7445.Am2017-3182 |
0.354 |
|
| 2017 |
Wang VE, Settleman J, McCormic F. Abstract 1209: FGFR inhibition re-sensitizes BRAF/MEK dual resistant cells to the BRAF/MEK inhibitor combination Cancer Research. 77: 1209-1209. DOI: 10.1158/1538-7445.Am2017-1209 |
0.408 |
|
| 2016 |
Pusapati R, Gao M, Daemen A, Hatzivassiliou G, Settleman J. Abstract B02: mTOR/S6K pathway-dependent metabolic reprogramming in cancer cells mediates resistance to glycolytic inhibitors Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Metca15-B02 |
0.358 |
|
| 2016 |
Savage HM, O’Brien C, Moore H, Lackner MR, Yauch R, Settleman J, Wilson TR. Abstract 372: Taselisib enhances the potency of ERBB inhibitors in biomarker-defined subsets of head and neck squamous carcinoma cell lines Cancer Research. 76: 372-372. DOI: 10.1158/1538-7445.Am2016-372 |
0.485 |
|
| 2015 |
Daemen A, Peterson D, Sahu N, McCord R, Du X, Liu B, Kowanetz K, Hong R, Moffat J, Gao M, Boudreau A, Mroue R, Corson L, O'Brien T, Qing J, ... ... Settleman J, et al. Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 112: E4410-7. PMID 26216984 DOI: 10.1073/Pnas.1501605112 |
0.302 |
|
| 2015 |
Nair PM, Flores H, Gogineni A, Marsters S, Lawrence DA, Kelley RF, Ngu H, Sagolla M, Komuves L, Bourgon R, Settleman J, Ashkenazi A. Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display. Proceedings of the National Academy of Sciences of the United States of America. 112: 5679-84. PMID 25902490 DOI: 10.1073/Pnas.1418962112 |
0.326 |
|
| 2015 |
Kim Y, Apetri M, Luo B, Settleman JE, Anderson KS. Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors. Molecular Cancer Research : McR. 13: 765-74. PMID 25573954 DOI: 10.1158/1541-7786.Mcr-14-0326 |
0.412 |
|
| 2015 |
Klijn C, Durinck S, Stawiski EW, Haverty PM, Jiang Z, Liu H, Degenhardt J, Mayba O, Gnad F, Liu J, Pau G, Reeder J, Cao Y, Mukhyala K, Selvaraj SK, ... ... Settleman J, et al. A comprehensive transcriptional portrait of human cancer cell lines. Nature Biotechnology. 33: 306-12. PMID 25485619 DOI: 10.1038/Nbt.3080 |
0.379 |
|
| 2015 |
Dompe NA, Lin E, Peng J, Chan G, Tien J, Merchant M, Bourgon R, Settleman J, Wilson T, Neve RM. Abstract B22: Potential combinatorial strategies to overcome drug resistance in BRAF-mutant melanoma Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-B22 |
0.362 |
|
| 2014 |
Lee GY, Haverty PM, Li L, Kljavin NM, Bourgon R, Lee J, Stern H, Modrusan Z, Seshagiri S, Zhang Z, Davis D, Stokoe D, Settleman J, de Sauvage FJ, Neve RM. Comparative oncogenomics identifies PSMB4 and SHMT2 as potential cancer driver genes. Cancer Research. 74: 3114-26. PMID 24755469 DOI: 10.1158/0008-5472.Can-13-2683 |
0.375 |
|
| 2014 |
Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene. 33: 1590-600. PMID 23542178 DOI: 10.1038/Onc.2013.92 |
0.469 |
|
| 2014 |
Willers H, Wang M, Han J, Kern A, Hülskötter M, Krause M, Baumann M, Benes C, Efstathiou J, Settleman J. Chromatin Condensation Mediated by EGFR and Aurora B Protects KRAS-Mutant Lung Cancer Cells Against Ionizing Radiation International Journal of Radiation Oncology*Biology*Physics. 90: S104. DOI: 10.1016/J.Ijrobp.2014.05.515 |
0.363 |
|
| 2013 |
Pei S, Minhajuddin M, Callahan KP, Balys M, Ashton JM, Neering SJ, Lagadinou ED, Corbett C, Ye H, Liesveld JL, O'Dwyer KM, Li Z, Shi L, Greninger P, Settleman J, et al. Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells. The Journal of Biological Chemistry. 288: 33542-58. PMID 24089526 DOI: 10.1074/Jbc.M113.511170 |
0.312 |
|
| 2013 |
Pfäffle HN, Wang M, Gheorghiu L, Ferraiolo N, Greninger P, Borgmann K, Settleman J, Benes CH, Sequist LV, Zou L, Willers H. EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity. Cancer Research. 73: 6254-63. PMID 23966292 DOI: 10.1158/0008-5472.Can-13-0044 |
0.496 |
|
| 2013 |
Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Piris A, Nazarian RM, Brown RD, Godfrey JT, Winokur D, Walsh J, Mino-Kenudson M, Maheswaran S, Settleman J, Wargo JA, Flaherty KT, et al. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Science Translational Medicine. 5: 196ra98. PMID 23903755 DOI: 10.1126/Scitranslmed.3005753 |
0.417 |
|
| 2013 |
Tan N, Wong M, Nannini MA, Hong R, Lee LB, Price S, Williams K, Savy PP, Yue P, Sampath D, Settleman J, Fairbrother WJ, Belmont LD. Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models. Molecular Cancer Therapeutics. 12: 853-64. PMID 23475955 DOI: 10.1158/1535-7163.Mct-12-0949 |
0.434 |
|
| 2013 |
Corcoran RB, Cheng KA, Hata AN, Faber AC, Ebi H, Coffee EM, Greninger P, Brown RD, Godfrey JT, Cohoon TJ, Song Y, Lifshits E, Hung KE, Shioda T, Dias-Santagata D, ... ... Settleman J, et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell. 23: 121-8. PMID 23245996 DOI: 10.1016/J.Ccr.2012.11.007 |
0.426 |
|
| 2013 |
Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Winokur D, Piris A, Nazarian RM, Brown RD, Godfrey JT, Mino-Kenudson M, Settleman J, Wargo JA, Flaherty KT, Haber DA, Engelman JA. Abstract 4568: Rapid assessment of TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF mutant melanoma. Cancer Research. 73: 4568-4568. DOI: 10.1158/1538-7445.Am2013-4568 |
0.387 |
|
| 2013 |
Wilson CR, Nicholes K, Bustos D, Lin E, Shi L, Kirkpatrick D, Settleman J. Abstract 4462: Resistance to selective kinase inhibitors upon epithelial to mesenchymal transition. Cancer Research. 73: 4462-4462. DOI: 10.1158/1538-7445.Am2013-4462 |
0.429 |
|
| 2013 |
Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Piris A, Nazarian RM, Brown RD, Godfrey JT, Winokur D, Walsh J, Mino-Kenudson M, Maheswaran S, Settleman J, Wargo JA, Flaherty KT, et al. Abstract C137: Rapid assessment of TORC1 suppression as a functional biomarker predicting responsiveness to RAF and MEK inhibitors in BRAF-mutant melanoma patients. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C137 |
0.397 |
|
| 2013 |
Corcoran RB, Cheng KA, Hata AN, Faber AC, Ebi H, Coffee EM, Greninger P, Brown RD, Godfrey JT, Cohoon TJ, Song Y, Lifshits E, Shioda T, Dias-Santagata D, Singh A, ... Settleman J, et al. Abstract PR09: Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS-mutant cancer models Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Pms-Pr09 |
0.432 |
|
| 2012 |
Kim Y, Li Z, Apetri M, Luo B, Settleman JE, Anderson KS. Temporal resolution of autophosphorylation for normal and oncogenic forms of EGFR and differential effects of gefitinib. Biochemistry. 51: 5212-22. PMID 22657099 DOI: 10.1021/Bi300476V |
0.387 |
|
| 2012 |
Hegedüs C, Truta-Feles K, Antalffy G, Várady G, Német K, Ozvegy-Laczka C, Kéri G, Orfi L, Szakács G, Settleman J, Váradi A, Sarkadi B. Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance. Biochemical Pharmacology. 84: 260-7. PMID 22548830 DOI: 10.1016/J.Bcp.2012.04.010 |
0.43 |
|
| 2012 |
Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, ... ... Settleman J, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 483: 570-5. PMID 22460902 DOI: 10.1038/Nature11005 |
0.384 |
|
| 2012 |
Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discovery. 2: 227-35. PMID 22448344 DOI: 10.1158/2159-8290.Cd-11-0341 |
0.454 |
|
| 2012 |
Nardi V, Song Y, Santamaria-Barria JA, Cosper AK, Lam Q, Faber AC, Boland GM, Yeap BY, Bergethon K, Scialabba VL, Tsao H, Settleman J, Ryan DP, Borger DR, Bhan AK, et al. Activation of PI3K signaling in Merkel cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1227-36. PMID 22261808 DOI: 10.1158/1078-0432.Ccr-11-2308 |
0.363 |
|
| 2012 |
Wilson KJ, Mill C, Lambert S, Buchman J, Wilson TR, Hernandez-Gordillo V, Gallo RM, Ades LM, Settleman J, Riese DJ. EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. Growth Factors (Chur, Switzerland). 30: 107-16. PMID 22260327 DOI: 10.3109/08977194.2011.649918 |
0.786 |
|
| 2012 |
Wilson KJ, Mill CP, Gallo RM, Cameron EM, VanBrocklin H, Settleman J, Riese DJ. The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist. The Biochemical Journal. 443: 133-44. PMID 22216880 DOI: 10.1042/Bj20110921 |
0.781 |
|
| 2012 |
Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Dias-Santagata D, Pelle PD, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M, et al. Abstract LB-350: EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition by vemurafenib Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-350 |
0.462 |
|
| 2012 |
Corcoran RB, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M, Engelman JA, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Pelle PD, et al. Abstract PR8: Insensitivity to RAF inhibition by vemurafenib in BRAF mutant colorectal cancer by EGFR-mediated reactivation of MAPK signaling Clinical Cancer Research. 18: PR8-PR8. DOI: 10.1158/1078-0432.MECHRES-PR8 |
0.3 |
|
| 2011 |
Mill CP, Zordan MD, Rothenberg SM, Settleman J, Leary JF, Riese DJ. ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer. Genes & Cancer. 2: 792-804. PMID 22393464 DOI: 10.1177/1947601911431080 |
0.778 |
|
| 2011 |
Ebi H, Corcoran RB, Singh A, Chen Z, Song Y, Lifshits E, Ryan DP, Meyerhardt JA, Benes C, Settleman J, Wong KK, Cantley LC, Engelman JA. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. The Journal of Clinical Investigation. 121: 4311-21. PMID 21985784 DOI: 10.1172/Jci57909 |
0.447 |
|
| 2011 |
Heckman-Stoddard BM, Vargo-Gogola T, Herrick MP, Visbal AP, Lewis MT, Settleman J, Rosen JM. P190A RhoGAP is required for mammary gland development. Developmental Biology. 360: 1-10. PMID 21945077 DOI: 10.1016/J.Ydbio.2011.09.006 |
0.301 |
|
| 2011 |
Wang M, Morsbach F, Sander D, Gheorghiu L, Nanda A, Benes C, Kriegs M, Krause M, Dikomey E, Baumann M, Dahm-Daphi J, Settleman J, Willers H. EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks. Cancer Research. 71: 6261-9. PMID 21852385 DOI: 10.1158/0008-5472.Can-11-0213 |
0.355 |
|
| 2011 |
Nelson EA, Sharma SV, Settleman J, Frank DA. A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation. Oncotarget. 2: 518-24. PMID 21680956 DOI: 10.18632/Oncotarget.296 |
0.406 |
|
| 2011 |
Corcoran RB, Contino G, Deshpande V, Tzatsos A, Conrad C, Benes CH, Levy DE, Settleman J, Engelman JA, Bardeesy N. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Research. 71: 5020-9. PMID 21586612 DOI: 10.1158/0008-5472.Can-11-0908 |
0.387 |
|
| 2011 |
Corcoran RB, Settleman J, Engelman JA. Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget. 2: 336-46. PMID 21505228 DOI: 10.18632/Oncotarget.262 |
0.367 |
|
| 2011 |
Tschöp K, Conery AR, Litovchick L, Decaprio JA, Settleman J, Harlow E, Dyson N. A kinase shRNA screen links LATS2 and the pRB tumor suppressor. Genes & Development. 25: 814-30. PMID 21498571 DOI: 10.1101/Gad.2000211 |
0.308 |
|
| 2011 |
Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS, Zhai B, Wan L, Gutierrez A, Lau AW, Xiao Y, Christie AL, Aster J, Settleman J, Gygi SP, et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature. 471: 104-9. PMID 21368833 DOI: 10.1038/Nature09732 |
0.399 |
|
| 2011 |
Ebi H, Corcoran RB, Singh A, Chen Z, Song Y, Lifshits E, Ryan DP, Meyerhardt JA, Benes C, Settleman J, Cantley LC, Wong K, Engelman JA. Abstract 956: Receptor tyrosine kinases, not KRAS, activate PI3K in KRAS mutant colorectal cancers Cancer Research. 71: 956-956. DOI: 10.1158/1538-7445.Am2011-956 |
0.462 |
|
| 2011 |
Nardi V, Song YC, Cosper AK, Lam Q, Barria JAS, Boland GM, Yeap B, Bergethon K, Scialabba VL, Settleman J, Ryan DP, Borger DR, Hoang MP, Bhan AK, Iafrate AJ, et al. Abstract 2210: Activation of PI3K in Merkel cell carcinoma Cancer Research. 71: 2210-2210. DOI: 10.1158/1538-7445.Am2011-2210 |
0.453 |
|
| 2011 |
Willers H, Wang M, Morsbach F, Sander D, Nanda A, Kriegs M, Krause M, Dikomey E, Baumann M, Settleman J. EGFR Inhibition Radiosensitizes NSCLC Cells via DNA Double-strand Break Inducible Senescence International Journal of Radiation Oncology*Biology*Physics. 81: S24. DOI: 10.1016/J.Ijrobp.2011.06.049 |
0.361 |
|
| 2010 |
Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Science Signaling. 3: ra84. PMID 21098728 DOI: 10.1126/Scisignal.2001148 |
0.465 |
|
| 2010 |
Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, ... ... Settleman J, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. The New England Journal of Medicine. 363: 1693-703. PMID 20979469 DOI: 10.1056/Nejmoa1006448 |
0.419 |
|
| 2010 |
Jeon CY, Kim HJ, Morii H, Mori N, Settleman J, Lee JY, Kim J, Kim SC, Park JB. Neurite outgrowth from PC12 cells by basic fibroblast growth factor (bFGF) is mediated by RhoA inactivation through p190RhoGAP and ARAP3. Journal of Cellular Physiology. 224: 786-94. PMID 20578246 DOI: 10.1002/Jcp.22184 |
0.357 |
|
| 2010 |
Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 29: 4741-51. PMID 20531305 DOI: 10.1038/Onc.2010.215 |
0.361 |
|
| 2010 |
Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, Clark JW, Isakoff SJ, Sequist LV, Engelman JA, Lynch TJ, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. Embo Molecular Medicine. 2: 146-58. PMID 20432502 DOI: 10.1002/Emmm.201000070 |
0.342 |
|
| 2010 |
Zhou W, Hur W, McDermott U, Dutt A, Xian W, Ficarro SB, Zhang J, Sharma SV, Brugge J, Meyerson M, Settleman J, Gray NS. A structure-guided approach to creating covalent FGFR inhibitors. Chemistry & Biology. 17: 285-95. PMID 20338520 DOI: 10.1016/J.Chembiol.2010.02.007 |
0.573 |
|
| 2010 |
Rothenberg SM, Mohapatra G, Rivera MN, Winokur D, Greninger P, Nitta M, Sadow PM, Sooriyakumar G, Brannigan BW, Ulman MJ, Perera RM, Wang R, Tam A, Ma XJ, Erlander M, ... ... Settleman J, et al. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Research. 70: 2158-64. PMID 20215515 DOI: 10.1158/0008-5472.Can-09-3458 |
0.351 |
|
| 2010 |
Settleman J. Modeling drug sensitivity and resistance in human tumor-derived cell lines Clinical Cancer Research. 16. DOI: 10.1158/Diag-10-Pl1-1 |
0.362 |
|
| 2010 |
Rothenberg SM, Mohapatra G, Rivera MN, Winokur D, Greninger P, Cohen EEW, Louis DN, Settleman J, Haber DA. Abstract 5757: A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers Cancer Research. 70: 5757-5757. DOI: 10.1158/1538-7445.Am10-5757 |
0.352 |
|
| 2010 |
Yee AJ, Wittner BS, Gentry J, Mahoney C, McCutcheon K, Singh A, Greninger P, Ma X, Erlander MG, Sharma SV, Haber DA, Shioda T, Settleman J, Ramaswamy S. Abstract 2203: Integrative analysis for efficient candidate oncogene discovery in cancer cell lines Cancer Research. 70: 2203-2203. DOI: 10.1158/1538-7445.Am10-2203 |
0.344 |
|
| 2010 |
Settleman J. Abstract IA2-1: Modeling drug sensitivity and resistance in human tumor-derived cell lines Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcmusa10-Ia2-1 |
0.36 |
|
| 2009 |
Lévay M, Settleman J, Ligeti E. Regulation of the substrate preference of p190RhoGAP by protein kinase C-mediated phosphorylation of a phospholipid binding site. Biochemistry. 48: 8615-23. PMID 19673492 DOI: 10.1021/Bi900667Y |
0.346 |
|
| 2009 |
Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4247-53. PMID 19667264 DOI: 10.1200/Jco.2009.22.6993 |
0.328 |
|
| 2009 |
McDermott U, Ames RY, Iafrate AJ, Maheswaran S, Stubbs H, Greninger P, McCutcheon K, Milano R, Tam A, Lee DY, Lucien L, Brannigan BW, Ulkus LE, Ma XJ, Erlander MG, ... ... Settleman J, et al. Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Research. 69: 3937-46. PMID 19366796 DOI: 10.1158/0008-5472.Can-08-4327 |
0.483 |
|
| 2009 |
Quinlan MP, Settleman J. Isoform-specific ras functions in development and cancer. Future Oncology (London, England). 5: 105-16. PMID 19243303 DOI: 10.2217/14796694.5.1.105 |
0.312 |
|
| 2009 |
Plentz R, Park JS, Rhim AD, Abravanel D, Hezel AF, Sharma SV, Gurumurthy S, Deshpande V, Kenific C, Settleman J, Majumder PK, Stanger BZ, Bardeesy N. Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology. 136: 1741-9.e6. PMID 19208345 DOI: 10.1053/J.Gastro.2009.01.008 |
0.359 |
|
| 2009 |
Sharma SV, Settleman J. ErbBs in lung cancer. Experimental Cell Research. 315: 557-71. PMID 18721806 DOI: 10.1016/J.Yexcr.2008.07.026 |
0.353 |
|
| 2008 |
Chin TM, Quinlan MP, Singh A, Sequist LV, Lynch TJ, Haber DA, Sharma SV, Settleman J. Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 6867-76. PMID 18980981 DOI: 10.1158/1078-0432.Ccr-08-0093 |
0.468 |
|
| 2008 |
Shen CH, Chen HY, Lin MS, Li FY, Chang CC, Kuo ML, Settleman J, Chen RH. Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration, and invasion. Cancer Research. 68: 7779-87. PMID 18829532 DOI: 10.1158/0008-5472.Can-08-0997 |
0.387 |
|
| 2008 |
Rothenberg SM, Engelman JA, Le S, Riese DJ, Haber DA, Settleman J. Modeling oncogene addiction using RNA interference. Proceedings of the National Academy of Sciences of the United States of America. 105: 12480-4. PMID 18711136 DOI: 10.1073/Pnas.0803217105 |
0.794 |
|
| 2008 |
Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, Digumarthy S, Muzikansky A, Irimia D, Settleman J, Tompkins RG, et al. Detection of mutations in EGFR in circulating lung-cancer cells. The New England Journal of Medicine. 359: 366-77. PMID 18596266 DOI: 10.1056/Nejmoa0800668 |
0.482 |
|
| 2008 |
Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L, Haber DA, Settleman J. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Research. 68: 4853-61. PMID 18559533 DOI: 10.1158/0008-5472.Can-07-6787 |
0.429 |
|
| 2008 |
Jiang W, Betson M, Mulloy R, Foster R, Lévay M, Ligeti E, Settleman J. p190A RhoGAP is a glycogen synthase kinase-3-beta substrate required for polarized cell migration. The Journal of Biological Chemistry. 283: 20978-88. PMID 18502760 DOI: 10.1074/Jbc.M802588200 |
0.363 |
|
| 2008 |
Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2442-9. PMID 18458038 DOI: 10.1200/Jco.2007.14.8494 |
0.445 |
|
| 2008 |
McDermott U, Iafrate AJ, Gray NS, Shioda T, Classon M, Maheswaran S, Zhou W, Choi HG, Smith SL, Dowell L, Ulkus LE, Kuhlmann G, Greninger P, Christensen JG, Haber DA, ... Settleman J, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Research. 68: 3389-95. PMID 18451166 DOI: 10.1158/0008-5472.Can-07-6186 |
0.452 |
|
| 2008 |
Quinlan MP, Settleman J. Explaining the preponderance of Kras mutations in human cancer: An isoform-specific function in stem cell expansion. Cell Cycle (Georgetown, Tex.). 7: 1332-5. PMID 18418066 DOI: 10.4161/Cc.7.10.5927 |
0.376 |
|
| 2008 |
Godin-Heymann N, Ulkus L, Brannigan BW, McDermott U, Lamb J, Maheswaran S, Settleman J, Haber DA. The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Molecular Cancer Therapeutics. 7: 874-9. PMID 18413800 DOI: 10.1158/1535-7163.Mct-07-2387 |
0.446 |
|
| 2008 |
McDermott U, Sharma SV, Settleman J. High-throughput lung cancer cell line screening for genotype-correlated sensitivity to an EGFR kinase inhibitor. Methods in Enzymology. 438: 331-41. PMID 18413259 DOI: 10.1016/S0076-6879(07)38023-3 |
0.431 |
|
| 2008 |
Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, Niwa-Kawakita M, Sweet-Cordero A, Sebolt-Leopold J, Shannon KM, Settleman J, Giovannini M, Jacks T. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nature Genetics. 40: 600-8. PMID 18372904 DOI: 10.1038/Ng.115 |
0.521 |
|
| 2008 |
Baum B, Settleman J, Quinlan MP. Transitions between epithelial and mesenchymal states in development and disease. Seminars in Cell & Developmental Biology. 19: 294-308. PMID 18343170 DOI: 10.1016/J.Semcdb.2008.02.001 |
0.317 |
|
| 2008 |
Engelman JA, Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy Current Opinion in Genetics and Development. 18: 73-79. PMID 18325754 DOI: 10.1016/J.Gde.2008.01.004 |
0.362 |
|
| 2008 |
Gupta P, Emdad L, Lebedeva IV, Sarkar D, Dent P, Curiel DT, Settleman J, Fisher PB. Targeted combinatorial therapy of non-small cell lung carcinoma using a GST-fusion protein of full-length or truncated MDA-7/IL-24 with Tarceva. Journal of Cellular Physiology. 215: 827-36. PMID 18270968 DOI: 10.1002/Jcp.21369 |
0.445 |
|
| 2008 |
Quinlan MP, Quatela SE, Philips MR, Settleman J. Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion. Molecular and Cellular Biology. 28: 2659-74. PMID 18268007 DOI: 10.1128/Mcb.01661-07 |
0.363 |
|
| 2008 |
Chen GC, Lee JY, Tang HW, Debnath J, Thomas SM, Settleman J. Genetic interactions between Drosophila melanogaster Atg1 and paxillin reveal a role for paxillin in autophagosome formation. Autophagy. 4: 37-45. PMID 17952025 DOI: 10.4161/Auto.5141 |
0.314 |
|
| 2007 |
Bernards A, Settleman J. GEFs in growth factor signaling. Growth Factors (Chur, Switzerland). 25: 355-61. PMID 18236214 DOI: 10.1080/08977190701830375 |
0.33 |
|
| 2007 |
Sharma SV, Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes & Development. 21: 3214-31. PMID 18079171 DOI: 10.1101/Gad.1609907 |
0.33 |
|
| 2007 |
McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, ... ... Settleman J, et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proceedings of the National Academy of Sciences of the United States of America. 104: 19936-41. PMID 18077425 DOI: 10.1073/pnas.0707498104 |
0.333 |
|
| 2007 |
Godin-Heymann N, Bryant I, Rivera MN, Ulkus L, Bell DW, Riese DJ, Settleman J, Haber DA. Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Research. 67: 7319-26. PMID 17671201 DOI: 10.1158/0008-5472.Can-06-4625 |
0.788 |
|
| 2007 |
Settleman J, Kurie JM. Drugging the bad "AKT-TOR" to overcome TKI-resistant lung cancer. Cancer Cell. 12: 6-8. PMID 17613432 DOI: 10.1016/J.Ccr.2007.06.010 |
0.46 |
|
| 2007 |
Riese DJ, Gallo RM, Settleman J. Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. 29: 558-65. PMID 17508401 DOI: 10.1002/Bies.20582 |
0.783 |
|
| 2007 |
Betson M, Settleman J. A rho-binding protein kinase C-like activity is required for the function of protein kinase N in Drosophila development. Genetics. 176: 2201-12. PMID 17507675 DOI: 10.1534/Genetics.107.072967 |
0.371 |
|
| 2007 |
Mulloy R, Ferrand A, Kim Y, Sordella R, Bell DW, Haber DA, Anderson KS, Settleman J. Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib Cancer Research. 67: 2325-2330. PMID 17332364 DOI: 10.1158/0008-5472.Can-06-4293 |
0.506 |
|
| 2007 |
Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nature Reviews. Cancer. 7: 169-81. PMID 17318210 DOI: 10.1038/Nrc2088 |
0.457 |
|
| 2007 |
Settleman J. PAK-in' up cGMP for the move. Cell. 128: 237-8. PMID 17254961 DOI: 10.1016/J.Cell.2007.01.002 |
0.401 |
|
| 2007 |
Emdad L, Lebedeva IV, Su ZZ, Gupta P, Sarkar D, Settleman J, Fisher PB. Combinatorial treatment of non-small-cell lung cancers with gefitinib and Ad.mda-7 enhances apoptosis-induction and reverses resistance to a single therapy. Journal of Cellular Physiology. 210: 549-59. PMID 17111370 DOI: 10.1002/Jcp.20906 |
0.41 |
|
| 2006 |
Sharma SV, Settleman J. Oncogenic shock: turning an activated kinase against the tumor cell. Cell Cycle (Georgetown, Tex.). 5: 2878-80. PMID 17218790 DOI: 10.4161/Cc.5.24.3598 |
0.435 |
|
| 2006 |
Wildenberg GA, Dohn MR, Carnahan RH, Davis MA, Lobdell NA, Settleman J, Reynolds AB. p120-catenin and p190RhoGAP regulate cell-cell adhesion by coordinating antagonism between Rac and Rho. Cell. 127: 1027-39. PMID 17129786 DOI: 10.1016/J.Cell.2006.09.046 |
0.385 |
|
| 2006 |
Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, Yuza Y, Classon M, Haber DA, Settleman J. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell. 10: 425-35. PMID 17097564 DOI: 10.1016/J.Ccr.2006.09.014 |
0.429 |
|
| 2006 |
Hakre S, Tussie-Luna MI, Ashworth T, Novina CD, Settleman J, Sharp PA, Roy AL. Opposing functions of TFII-I spliced isoforms in growth factor-induced gene expression. Molecular Cell. 24: 301-8. PMID 17052463 DOI: 10.1016/J.Molcel.2006.09.005 |
0.362 |
|
| 2006 |
Bradley WD, Hernández SE, Settleman J, Koleske AJ. Integrin signaling through Arg activates p190RhoGAP by promoting its binding to p120RasGAP and recruitment to the membrane. Molecular Biology of the Cell. 17: 4827-36. PMID 16971514 DOI: 10.1091/Mbc.E06-02-0132 |
0.337 |
|
| 2006 |
Sebastian S, Settleman J, Reshkin SJ, Azzariti A, Bellizzi A, Paradiso A. The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochimica Et Biophysica Acta. 1766: 120-39. PMID 16889899 DOI: 10.1016/J.Bbcan.2006.06.001 |
0.474 |
|
| 2006 |
Verdier V, Johndrow JE, Betson M, Chen GC, Hughes DA, Parkhurst SM, Settleman J. Drosophila Rho-kinase (DRok) is required for tissue morphogenesis in diverse compartments of the egg chamber during oogenesis. Developmental Biology. 297: 417-32. PMID 16887114 DOI: 10.1016/J.Ydbio.2006.05.016 |
0.333 |
|
| 2006 |
Verdier V, Guang-Chao-Chen, Settleman J. Rho-kinase regulates tissue morphogenesis via non-muscle myosin and LIM-kinase during Drosophila development. Bmc Developmental Biology. 6: 38. PMID 16882341 DOI: 10.1186/1471-213X-6-38 |
0.386 |
|
| 2006 |
Haber DA, Bell DW, Sordella R, Kwak EL, Godin-Heymann N, Sharma SV, Lynch TJ, Settleman J. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harbor Symposia On Quantitative Biology. 70: 419-26. PMID 16869779 DOI: 10.1101/Sqb.2005.70.043 |
0.48 |
|
| 2006 |
Sharma SV, Fischbach MA, Haber DA, Settleman J. "Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4392s-4395s. PMID 16857816 DOI: 10.1158/1078-0432.Ccr-06-0096 |
0.41 |
|
| 2006 |
Lynch TJ, Adjei AA, Bunn PA, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Jänne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, ... Settleman J, et al. Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4365s-4371s. PMID 16857812 DOI: 10.1158/1078-0432.Ccr-06-1005 |
0.529 |
|
| 2006 |
Fischbach MA, Settleman J. Regulation of the nucleotide state of oncogenic ras proteins by nucleoside diphosphate kinase. Methods in Enzymology. 407: 33-45. PMID 16757312 DOI: 10.1016/S0076-6879(05)07004-7 |
0.344 |
|
| 2006 |
Ligeti E, Settleman J. Regulation of RhoGAP specificity by phospholipids and prenylation. Methods in Enzymology. 406: 104-17. PMID 16472653 DOI: 10.1016/S0076-6879(06)06009-5 |
0.304 |
|
| 2006 |
Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, Christensen JG, Settleman J, Haber DA. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proceedings of the National Academy of Sciences of the United States of America. 103: 2316-21. PMID 16461907 DOI: 10.1073/Pnas.0508776103 |
0.439 |
|
| 2006 |
Xu H, Szczur K, Zheng Y, Settleman J, Williams DA, Filippi M. P190-B RhoGAP Is Critical for Hematopoietic Stem/Progenitor Cell Homing and Short Term Engraftment. Blood. 108: 1341-1341. DOI: 10.1182/Blood.V108.11.1341.1341 |
0.309 |
|
| 2005 |
Bernards A, Settleman J. GAPs in growth factor signalling. Growth Factors (Chur, Switzerland). 23: 143-9. PMID 16019436 DOI: 10.1080/08977190500130480 |
0.366 |
|
| 2005 |
Haber DA, Settleman J. Overcoming acquired resistance to Iressa/Tarceva with inhibitors of a different class. Cell Cycle (Georgetown, Tex.). 4: 1057-9. PMID 15970680 DOI: 10.4161/Cc.4.8.1874 |
0.44 |
|
| 2005 |
Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, ... Settleman J, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proceedings of the National Academy of Sciences of the United States of America. 102: 7665-70. PMID 15897464 DOI: 10.1073/Pnas.0502860102 |
0.48 |
|
| 2005 |
Settleman J. Intercalating Arabidopsis leaf cells: a jigsaw puzzle of lobes, necks, ROPs, and RICs. Cell. 120: 570-2. PMID 15766519 DOI: 10.1016/J.Cell.2005.02.025 |
0.319 |
|
| 2005 |
Chen GC, Turano B, Ruest PJ, Hagel M, Settleman J, Thomas SM. Regulation of Rho and Rac signaling to the actin cytoskeleton by paxillin during Drosophila development. Molecular and Cellular Biology. 25: 979-87. PMID 15657426 DOI: 10.1128/Mcb.25.3.979-987.2005 |
0.343 |
|
| 2005 |
Jiang W, Sordella R, Chen GC, Hakre S, Roy AL, Settleman J. An FF domain-dependent protein interaction mediates a signaling pathway for growth factor-induced gene expression Molecular Cell. 17: 23-35. PMID 15629714 DOI: 10.1016/J.Molcel.2004.11.024 |
0.342 |
|
| 2005 |
Filippi M, Szczur K, Xu H, Zheng Y, Settleman J, Williams DA. Regulation of the Rho GTPase, RhoA, Activity Is Critical for Erythropoiesis during Embryo Development. Blood. 106: 829-829. DOI: 10.1182/Blood.V106.11.829.829 |
0.322 |
|
| 2005 |
Settleman J. Mutated kinases as targets for cancer drugs Drug Discovery Today: Disease Mechanisms. 2: 139-144. DOI: 10.1016/J.Ddmec.2005.05.006 |
0.443 |
|
| 2004 |
Settleman J. Inhibition of mutant EGF receptors by gefitinib: targeting an Achilles' heel of lung cancer. Cell Cycle (Georgetown, Tex.). 3: 1496-7. PMID 15539955 DOI: 10.4161/Cc.3.12.1325 |
0.486 |
|
| 2004 |
Song YH, Mirey G, Betson M, Haber DA, Settleman J. The Drosophila ATM ortholog, dATM, mediates the response to ionizing radiation and to spontaneous DNA damage during development. Current Biology : Cb. 14: 1354-9. PMID 15296752 DOI: 10.1016/J.Cub.2004.06.064 |
0.337 |
|
| 2004 |
Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science (New York, N.Y.). 305: 1163-7. PMID 15284455 DOI: 10.1126/Science.1101637 |
0.496 |
|
| 2004 |
Bernards A, Settleman J. GAP control: regulating the regulators of small GTPases. Trends in Cell Biology. 14: 377-85. PMID 15246431 DOI: 10.1016/J.Tcb.2004.05.003 |
0.351 |
|
| 2004 |
Kontaridis MI, Eminaga S, Fornaro M, Zito CI, Sordella R, Settleman J, Bennett AM. SHP-2 positively regulates myogenesis by coupling to the Rho GTPase signaling pathway. Molecular and Cellular Biology. 24: 5340-52. PMID 15169898 DOI: 10.1128/Mcb.24.12.5340-5352.2004 |
0.351 |
|
| 2004 |
Barker TH, Grenett HE, MacEwen MW, Tilden SG, Fuller GM, Settleman J, Woods A, Murphy-Ullrich J, Hagood JS. Thy-1 regulates fibroblast focal adhesions, cytoskeletal organization and migration through modulation of p190 RhoGAP and Rho GTPase activity. Experimental Cell Research. 295: 488-96. PMID 15093746 DOI: 10.1016/J.Yexcr.2004.01.026 |
0.385 |
|
| 2004 |
Hernández SE, Settleman J, Koleske AJ. Adhesion-dependent regulation of p190RhoGAP in the developing brain by the Abl-related gene tyrosine kinase. Current Biology : Cb. 14: 691-6. PMID 15084284 DOI: 10.1016/J.Cub.2004.03.062 |
0.388 |
|
| 2004 |
Chen GC, Gajowniczek P, Settleman J. Rho-LIM kinase signaling regulates ecdysone-induced gene expression and morphogenesis during Drosophila metamorphosis. Current Biology : Cb. 14: 309-13. PMID 14972681 DOI: 10.1016/J.Cub.2004.01.056 |
0.378 |
|
| 2004 |
Ligeti E, Dagher MC, Hernandez SE, Koleske AJ, Settleman J. Phospholipids can switch the GTPase substrate preference of a GTPase-activating protein. The Journal of Biological Chemistry. 279: 5055-8. PMID 14699145 DOI: 10.1074/Jbc.C300547200 |
0.337 |
|
| 2003 |
Wennerberg K, Forget MA, Ellerbroek SM, Arthur WT, Burridge K, Settleman J, Der CJ, Hansen SH. Rnd proteins function as RhoA antagonists by activating p190 RhoGAP. Current Biology : Cb. 13: 1106-15. PMID 12842009 DOI: 10.1016/S0960-9822(03)00418-4 |
0.334 |
|
| 2003 |
Sordella R, Jiang W, Chen G, Curto M, Settleman J. Modulation of Rho GTPase Signaling Regulates a Switch between Adipogenesis and Myogenesis Cell. 113: 147-158. PMID 12705864 DOI: 10.1016/S0092-8674(03)00271-X |
0.379 |
|
| 2002 |
Sordella R, Classon M, Hu KQ, Matheson SF, Brouns MR, Fine B, Zhang L, Takami H, Yamada Y, Settleman J. Modulation of CREB activity by the Rho GTPase regulates cell and organism size during mouse embryonic development. Developmental Cell. 2: 553-65. PMID 12015964 DOI: 10.1016/S1534-5807(02)00162-4 |
0.349 |
|
| 2001 |
Settleman J. Rac 'n Rho: the music that shapes a developing embryo. Developmental Cell. 1: 321-331. PMID 11702944 DOI: 10.1016/S1534-5807(01)00053-3 |
0.309 |
|
| 2001 |
Molnár G, Dagher MC, Geiszt M, Settleman J, Ligeti E. Role of prenylation in the interaction of Rho-family small GTPases with GTPase activating proteins. Biochemistry. 40: 10542-9. PMID 11523996 DOI: 10.1021/Bi011158E |
0.3 |
|
| 2001 |
Brouns MR, Matheson SF, Settleman J. p190 RhoGAP is the principal Src substrate in brain and regulates axon outgrowth, guidance and fasciculation. Nature Cell Biology. 3: 361-7. PMID 11283609 DOI: 10.1038/35070042 |
0.316 |
|
| 2000 |
Zrihan-Licht S, Fu Y, Settleman J, Schinkmann K, Shaw L, Keydar I, Avraham S, Avraham H. RAFTK/Pyk2 tyrosine kinase mediates the association of p190 RhoGAP with RasGAP and is involved in breast cancer cell invasion. Oncogene. 19: 1318-28. PMID 10713673 DOI: 10.1038/Sj.Onc.1203422 |
0.45 |
|
| 1999 |
Vincent S, Settleman J. Inhibition of RhoGAP activity is sufficient for the induction of Rho-mediated actin reorganization. European Journal of Cell Biology. 78: 539-48. PMID 10494860 DOI: 10.1016/S0171-9335(99)80019-3 |
0.337 |
|
| 1999 |
Lu Y, Settleman J. The Drosophila Pkn protein kinase is a Rho/Rac effector target required for dorsal closure during embryogenesis. Genes & Development. 13: 1168-1180. PMID 10323867 DOI: 10.1101/Gad.13.9.1168 |
0.423 |
|
| 1999 |
Settleman J. Rho GTPases in Development Progress in Molecular and Subcellular Biology. 22: 201-229. PMID 10081071 DOI: 10.1007/978-3-642-58591-3_10 |
0.339 |
|
| 1998 |
Nolan KM, Barrett K, Lu Y, Hu KQ, Vincent S, Settleman J. Myoblast city, the Drosophila homolog of DOCK180/CED-5, is required in a Rac signaling pathway utilized for multiple developmental processes Genes and Development. 12: 3337-3342. PMID 9808621 DOI: 10.1101/Gad.12.21.3337 |
0.355 |
|
| 1998 |
Maheswaran S, Englert C, Lee SB, Ezzel RM, Settleman J, Haber DA. E1B 55K sequesters WT1 along with p53 within a cytoplasmic body in adenovirus-transformed kidney cells. Oncogene. 16: 2041-50. PMID 9572485 DOI: 10.1038/Sj.Onc.1201741 |
0.317 |
|
| 1997 |
Barrett K, Leptin M, Settleman J. The Rho GTPase and a putative RhoGEF mediate a signaling pathway for the cell shape changes in Drosophila gastrulation. Cell. 91: 905-15. PMID 9428514 DOI: 10.1016/S0092-8674(00)80482-1 |
0.341 |
|
| 1997 |
Vincent S, Settleman J. The PRK2 kinase is a potential effector target of both Rho and Rac GTPases and regulates actin cytoskeletal organization. Molecular and Cellular Biology. 17: 2247-56. PMID 9121475 DOI: 10.1128/Mcb.17.4.2247 |
0.378 |
|
| 1997 |
Hu K, Settleman J. Tandem SH2 binding sites mediate the RasGAP-RhoGAP interaction: a conformational mechanism for SH3 domain regulation The Embo Journal. 16: 473-483. PMID 9034330 DOI: 10.1093/Emboj/16.3.473 |
0.312 |
|
| 1996 |
Foster R, Hu KQ, Lu Y, Nolan KM, Thissen J, Settleman J. Identification of a novel human Rho protein with unusual properties: GTPase deficiency and in vivo farnesylation Molecular and Cellular Biology. 16: 2689-2699. PMID 8649376 DOI: 10.1128/Mcb.16.6.2689 |
0.305 |
|
| 1995 |
Settleman J, Foster R. [13] Purification and GTPase-activating protein activity of baculovirus expressed p190 Methods in Enzymology. 256: 105-113. PMID 7476422 DOI: 10.1016/0076-6879(95)56015-7 |
0.323 |
|
| 1995 |
Hariharan IK, Hu K, Asha H, Quintanilla A, Ezzell RM, Settleman J. Characterization of rho GTPase family homologues in Drosophila melanogaster: overexpressing Rho1 in retinal cells causes a late developmental defect. The Embo Journal. 14: 292-302. DOI: 10.1002/J.1460-2075.1995.Tb07003.X |
0.359 |
|
| 1994 |
Foster R, Hu K, Shaywitz DA, Settleman J. p190 RhoGAP, the major RasGAP-associated protein, binds GTP directly. Molecular and Cellular Biology. 14: 7173-7181. PMID 7935432 DOI: 10.1128/Mcb.14.11.7173 |
0.302 |
|
| 1993 |
Hwang ES, Riese DJ, Settleman J, Nilson LA, Honig J, Flynn S, DiMaio D. Inhibition of cervical carcinoma cell line proliferation by the introduction of a bovine papillomavirus regulatory gene. Journal of Virology. 67: 3720-9. PMID 8389903 DOI: 10.1128/Jvi.67.7.3720-3729.1993 |
0.727 |
|
| 1990 |
Riese DJ, Settleman J, Neary K, DiMaio D. Bovine papillomavirus E2 repressor mutant displays a high-copy-number phenotype and enhanced transforming activity. Journal of Virology. 64: 944-9. PMID 2153255 DOI: 10.1128/Jvi.64.2.944-949.1990 |
0.759 |
|
| 1990 |
SETTLEMAN J, HINDS P, COBRINIK D, JACKS T, MITTNACHT S, TEMPLETON D, PARK S, WEINBERG R. Studies on the mechanism of cell growth suppression by the retinoblastoma gene Cell Biology International Reports. 14: 21. DOI: 10.1016/0309-1651(90)90195-5 |
0.519 |
|
| 1989 |
Settleman J, Fazeli A, Malicki J, Horwitz BH, DiMaio D. Genetic evidence that acute morphologic transformation, induction of cellular DNA synthesis, and focus formation are mediated by a single activity of the bovine papillomavirus E5 protein. Molecular and Cellular Biology. 9: 5563-5572. PMID 2555701 DOI: 10.1128/Mcb.9.12.5563 |
0.61 |
|
| 1989 |
Horwitz BH, Settleman J, Prakash SS, DiMaio D. Structure, activity, and regulation of the bovine papillomavirus E5 gene and its transforming protein product Current Topics in Microbiology and Immunology. 144: 143-151. PMID 2551579 DOI: 10.1007/978-3-642-74578-2_18 |
0.537 |
|
| 1988 |
Settleman J, Dimaio D. Efficient transactivation and morphologic transformation by bovine papillomavirus genes expressed from a bovine papillomavirus/simian virus 40 recombinant virus. Proceedings of the National Academy of Sciences of the United States of America. 85: 9007-9011. PMID 2848252 DOI: 10.1073/Pnas.85.23.9007 |
0.59 |
|
| 1988 |
Prakash SS, Horwitz BH, Zibello T, Settleman J, DiMaio D. Bovine papillomavirus E2 gene regulates expression of the viral E5 transforming gene Journal of Virology. 62: 3608-3613. PMID 2843663 DOI: 10.1128/Jvi.62.10.3608-3613.1988 |
0.574 |
|
| 1988 |
DiMaio D, Settleman J. Bovine papillomavirus mutant temperature sensitive for transformation, replication and transactivation. The Embo Journal. 7: 1197-1204. DOI: 10.1002/J.1460-2075.1988.Tb02931.X |
0.603 |
|
| Show low-probability matches. |